home / stock / azrx / azrx news

AZRX News and Press, AzurRx BioPharma Inc. From 09/08/21

Stock Information
Company Name: AzurRx BioPharma Inc.
Stock Symbol: AZRX
Market: NASDAQ
Website: azurrx.com
Menu
AZRX AZRX Quote AZRX Short AZRX News AZRX Articles AZRX Message Board
Get AZRX Alerts

News, Short Squeeze, Breakout and More Instantly...
AZRX - AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

BOCA RATON, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ...
AZRX - AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced...

AZRX - 3 Penny Stocks That Top Investors Are Buying Right Now

Why Penny Stocks Investors Are Watching These 3 Small-Caps Finding the best penny stocks to buy is a mixture of strategy and research. And, one metric that some penny stocks investors use is to find out what top investors are buying. This can be a great strategy to utilize, however ...

AZRX - AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in  AzurRx Biopharma  (NASDAQ: AZRX ) are seeing impressive gains. Indeed, AZRX stock is currently more than 30% higher today, trading on extremely heavy volume. More than 103 million sha...
AZRX - SLI, XAIR, MBII among mid-day movers

Gainers: PharmaCyte Biotech (NASDAQ:PMCB) +118%. Virpax Pharmaceuticals (NASDAQ:VRPX) +59%. SGOCO Group (NASDAQ:SGOC) +53%. AzurRx BioPharma (NASDAQ:AZRX) +30%. NRx Pharmaceuticals (NASDAQ:NRXP) +26%. Standard Lithium (NYSE:SLI) +21%. ESSA Pharma (NASDAQ:EPIX) +15%. Agrify (NASDAQ:AGFY) +17%....

AZRX - AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary endpoint 20-patient study suggests combination therapy ma...

AZRX - AzurRx BioPharma Announces WHO Publication of "Adrulipase Alfa" as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the ...
AZRX - AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) ( NASDAQ: AZRX ), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the...

AZRX - AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Aug. 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma , Inc. (“AzurRx” or the “Company”) ( NASDAQ: AZRX ), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announce...

AZRX - AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma , Inc. (“AzurRx” or the “Company”) ( NASDAQ: AZRX ), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) disease...
Previous 10 Next 10